These discoveries provide guidance for precision radiotherapy in prostate cancer: PARP1-EJ repair switching can serve as a criterion for patient selection, while effectively inducing tumor cell senescence is a key mechanism for successful treatment. The gene discussed is PARP1; the disease is Familial prostate cancer.